Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Indolent Non-Hodgkin Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT05418088
What this trial is testing

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Who this might be right for
Recurrent Acute Lymphoblastic LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRecurrent B-Cell Prolymphocytic Leukemia+15 more
Sumithira Vasu 54
Testing effectiveness (Phase 2)Looking for participantsNCT06986174
What this trial is testing

Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

Who this might be right for
Waldenström MacroglobulinemiaLymphoplasmacytic LymphomaB-Cell Lymphoproliferative Disorder+1 more
Shayna Sarosiek, MD 30
Testing effectiveness (Phase 2)Looking for participantsNCT03571568
What this trial is testing

BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL

Who this might be right for
Indolent B-Cell Non-Hodgkin Lymphoma
BioInvent International AB 140
Testing effectiveness (Phase 2)Study completedNCT00086034
What this trial is testing

Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma

Who this might be right for
LymphomaNon-Hodgkin's Lymphoma
Pharmacyclics LLC. 35
Testing effectiveness (Phase 2)Ended earlyNCT00768339
What this trial is testing

A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas

Who this might be right for
Leukemia, Lymphocytic, Chronic, B-CellLymphoma, B-Cell
Aegera Therapeutics 25
Testing effectiveness (Phase 2)Looking for participantsNCT05672251
What this trial is testing

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Grade 3b Follicular LymphomaRecurrent High Grade B-Cell Lymphoma+9 more
City of Hope Medical Center 36
Early research (Phase 1)Study completedNCT03019666
What this trial is testing

Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL

Who this might be right for
Multiple MyelomaNon-Hodgkin LymphomaDiffuse Large B Cell Lymphoma+5 more
Masonic Cancer Center, University of Minnesota 39
Testing effectiveness (Phase 2)WithdrawnNCT00837174
What this trial is testing

Relapsed and/or Refractory Non-Hodgkin Lymphoma Study

Who this might be right for
Non-Hodgkin Lymphoma
The Methodist Hospital Research Institute
Early research (Phase 1)Active Not RecruitingNCT05878184
What this trial is testing

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

Who this might be right for
Non Hodgkin LymphomaChronic Lymphocytic Leukemia
Sana Biotechnology 16
Early research (Phase 1)Ended earlyNCT05336409
What this trial is testing

CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

Who this might be right for
R/R CD19-Positive B-Cell MalignanciesIndolent Non-Hodgkin LymphomaAggressive Non-Hodgkin Lymphoma
Century Therapeutics, Inc. 28
Testing effectiveness (Phase 2)Study completedNCT00980395
What this trial is testing

Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma

Who this might be right for
LymphomaMantle Cell LymphomaIndolent Lymphoma+1 more
University of Arizona 24
Early research (Phase 1)WithdrawnNCT04635683
What this trial is testing

Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Who this might be right for
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueRecurrent Follicular Lymphoma+21 more
Yazeed Sawalha
Early research (Phase 1)Study completedNCT02049541
What this trial is testing

Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma

Who this might be right for
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Grade 1 Follicular Lymphoma+6 more
Kami Maddocks, MD 18
Early research (Phase 1)Study completedNCT05359211
What this trial is testing

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular Lymphoma+6 more
Fred Hutchinson Cancer Center 27
Early research (Phase 1)Looking for participantsNCT05755087
What this trial is testing

Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell TypeRecurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell TypeRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements+6 more
Lapo Alinari
Testing effectiveness (Phase 2)Study completedNCT00406809
What this trial is testing

ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

Who this might be right for
Chronic Lymphoid LeukemiaLymphoid MalignanciesNon-Hodgkin's Lymphoma+3 more
AbbVie (prior sponsor, Abbott) 81
Testing effectiveness (Phase 2)Study completedNCT02342665
What this trial is testing

Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL

Who this might be right for
Lymphoma Non-Hodgkin
Bayer 25
Testing effectiveness (Phase 2)Study completedNCT02207062
What this trial is testing

Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma

Who this might be right for
Recurrent Transformed B-Cell Non-Hodgkin LymphomaRefractory Transformed B-Cell Non-Hodgkin Lymphoma
University of Washington 20
Early research (Phase 1)Study completedNCT02242045
What this trial is testing

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)

Who this might be right for
Chronic Lymphocytic LeukemiaIndolent Non-Hodgkin LymphomaFollicular Lymphoma+3 more
Gilead Sciences 6
Testing effectiveness (Phase 2)Study completedNCT00426855
What this trial is testing

Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)

Who this might be right for
Lymphoma, Non-Hodgkin
Peter Moosmann 12
Next Page
18